Gardasil for boys gets PBAC green light

Minutes from the November meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) released today show it now supports the move towards a “gender neutral program” involving the HPV vaccine.

The recommendation to government is for the NIP’s Gardasil vaccination program to be extended to include boys aged 12–13 years, plus a catch-up program over two years for males in Year 9.

CSL first applied for boys to also be given the cancer and genital wart-preventing vaccine in a submission made in November 2010, but this was rejected on economic grounds by the PBAC in March this year.

Latest

Trending